This protocol describes a detailed procedure for the construction of a phage-displayed synthetic antibody library with tailored diversity. Synthetic antibodies have broad applications from basic research to disease diagnostics and therapeutics.
A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
* These authors contributed equally
This protocol describes a detailed procedure for the construction of a phage-displayed synthetic antibody library with tailored diversity. Synthetic antibodies have broad applications from basic research to disease diagnostics and therapeutics.
Demand for monoclonal antibodies (mAbs) in basic research and medicine is increasing yearly. Hybridoma technology has been the dominant method for mAb development since its first report in 1975. As an alternative technology, phage display methods for mAb development are increasingly attractive since Humira, the first phage-derived antibody and one of the best-selling mAbs, was approved for clinical treatment of rheumatoid arthritis in 2002. As a non-animal based mAb development technology, phage display bypasses antigen immunogenicity, humanization, and animal maintenance that are required from traditional hybridoma technology based antibody development. In this protocol, we describe a method for construction of synthetic phage-displayed Fab libraries with diversities of 109-1010 obtainable with a single electroporation. This protocol consists of: 1) high-efficiency electro-competent cell preparation; 2) extraction of uracil-containing single-stranded DNA (dU-ssDNA); 3) Kunkel's method based oligonucleotide-directed mutagenesis; 4) electroporation and calculation of library size; 5) protein A/L-based enzyme-linked immunosorbent assay (ELISA) for folding and functional diversity evaluation; and 6) DNA sequence analysis of diversity.
mAbs have broad applications ranging from basic research to disease diagnostics and therapeutics. As of 2016, more than 60 mAbs have been approved by the United States Food and Drug Administration (USFDA) for clinical treatment of autoimmune diseases, cancer, and infectious diseases1,2.
In 1975, Kohler and Milstein reported a technique for the continuous generation of antibodies of a single clonal specificity from a cellular source referred to as 'hybridomas' and this technique has subsequently become a cornerstone in medicine and industry3,
Access restricted. Please log in or start a trial to view this content.
NOTE: Filter sterile tips must be used throughout when dealing with phage to avoid contamination to pipette gun and surrounding area. Aseptic area or hood must be used when handling with bacteria and phage experiments. Phage experiment area must be cleaned up using 2% sodium dodecyl sulfate (SDS) followed by 70% ethanol to avoid phage contamination. For making serial dilutions in this protocol, new tips should be used for each dilution.
1. E. Coli SS320 Electro-competent Cell Preparation
Access restricted. Please log in or start a trial to view this content.
Following the flow chart of the Fab library construction (see Figure 1), we prepared M13KO7 helper phage pre-infected E. coli SS320 electro-competent cells. The efficiency of these electro-competent cells is estimated as 2 X 109 cfu/µg when the Fab phagemid backbone for library construction was used (Figure 4).
The uracil incorporation efficiency by .......
Access restricted. Please log in or start a trial to view this content.
To construct high diversity, phage-displayed Fab libraries, quality control check points are needed to monitor various stages of the construction process, including the competency of electro-competent cells, quality of the dU-ssDNA template, efficiency of CCC-dsDNA synthesis, titer after electroporation, Fab folding, and amino acid diversity of CDRs by sequence analysis of Fab-phage clones.
High yield and purity of dU-ssDNA is essential for high mutagenesis rate. In our experience, phage induc.......
Access restricted. Please log in or start a trial to view this content.
The authors have nothing to disclose.
The authors appreciate Dr. Frederic Fellouse from the Sidhu lab for critical comments on Kunkel's method based synthetic Fab phage library construction. The authors appreciate Mrs. Alevtina Pavlenco and other members from the Sidhu lab for valuable help of preparing high-efficiency electro-competent E. coli cells and high quality dU-ssDNA. This work was supported by National Natural Science Foundation of China (Grant No.: 81572698, 31771006) to DW and by ShanghaiTech University (Grant No.: F-0301-13-005) to Laboratory of Antibody Engineering.
....Access restricted. Please log in or start a trial to view this content.
| Name | Company | Catalog Number | Comments |
|---|---|---|---|
| Reagents | |||
| 1.0 M H3PO4 | Fisher | AC29570 | |
| 1.0 M Tris, pH 8.0 | Invitrogen | 15568-025 | |
| 10 mM ATP | Invitrogen | 18330-019 | |
| 100 mM dithiothreitol | Fisher | BP172 | |
| 100 mM dNTP mix | GE Healthcare | 28-4065-60 | solution containing 25 mM each of dATP, dCTP, dGTP and dTTP. |
| 3,3’,5,5’-tetramethylbenzidine (TMB) | Kirkegaard & Perry Laboratories Inc | 50-76-02 | |
| 50X TAE | Invitrogen | 24710030 | |
| Agarose | Fisher | BP160 | |
| Carbenicillin, carb | Sigma | C1389 | 100 mg/mL in water, 0.22 μm filter-sterilize, work concentration: 100 μg/mL. |
| Chloramphenicol, cmp | Sigma | C0378 | 100 mg/mL in ethanol, 0.22 μm filter-sterilize, work concentration: 10 μg/mL. |
| EDTA 0.5 M, pH 8.0 | Invitrogen | AM9620G | |
| Granulated agar | VWR | J637-500G | |
| H2O2 peroxidase substrate | Kirkegaard & Perry Laboratories Inc | 50-65-02 | |
| K2HPO4 | Sigma | 795488 | |
| Kanamycin, kan | Fisher | AC61129 | 50 mg/mL in water, 0.22 μm filter-sterilize, work concentration: 50 μg/mL. |
| KH2PO4 | Sigma | P2222 | |
| Na2HPO4 | Sigma | 94046 | |
| NaCl | Alfa Aesar | U19C015 | |
| Nanodrop | Fisher | ND2000C | |
| NaOH | Fisher | SS256 | ! CAUTION NaOH causes burns. |
| NON-Fat Powdered Milk | Sangon Biotech | A600669 | |
| PEG-8000 | Fisher | BP233 | |
| Protein A-HRP conjugate | Invitrogen | 101123 | |
| QIAprep Spin M13 Kit | Qiagen | 22704 | |
| QIAquick Gel Extraction Kit | Qiagen | 28706 | |
| QIAquick PCR Purification Kit | Qiagen | 28104 | |
| Recombinant Protein L | Fisher | 77679 | |
| T4 DNA polymerase | New England Biolabs | M0203S | |
| T4 polynucleotide kinase | New England Biolabs | M0201S | |
| T7 DNA polymerase | New England Biolabs | M0274S | |
| Tetracycline, tet | Sigma | T7660 | 50 mg/mL in water, 0. 22 μm filter-sterilize, work concentration: 10 μg/mL. |
| Tryptone | Fisher | 0123-07-5 | |
| Tween-20 | Sigma | P2287 | |
| Ultrapure glycerol | Invitrogen | 15514-011 | |
| Uridine | Sigma | U3750 | 25 mg/mL in ethanol, work concentration: 0.25 μg/mL. |
| Yeast extract | VWR | DF0127-08 | |
| Name | Company | Catalog Number | Comments |
| Strains | |||
| E.coli CJ236 | New England Biolabs | E4141 | Genotype: dut- ung- thi-1 relA1 spoT1 mcrA/pCJ105(F' camr). Used for preparation of dU-ssDNA. |
| E.coli SS320 | Lucigen | 60512 | Genotype: [F'proAB+lacIq lacZΔM15 Tn10 (tetr)] hsdR mcrB araD139 Δ(araABC-leu)7679 ΔlacX74 galUgalK rpsL thi. Optimized for high-efficiency electroporation and filamentous bacteriophage production. |
| M13KO7 | New England Biolabs | N0315S | |
| Name | Company | Catalog Number | Comments |
| Equipment | |||
| 0.2-cm gap electroporation cuvette | BTX | ||
| 96-well 2mL Deep-well plates | Fisher | 278743 | |
| 96-well Maxisorp immunoplates | Nunc | 151759 | |
| Baffled flasks | Corning | ||
| Benchtop centrifuge | Eppendorf | 5811000096 | |
| Centrifuge bottles | Nalgene | ||
| ECM-630 electroporator | BTX | ||
| Magnetic stir bars | Nalgene | ||
| Thermo Fisher centrifuge | Fisher | ||
| High speed shaker | TAITEK | MBR-034P | |
| Microplate shaker | QILINBEIER | QB-9002 | |
| Liquid handler for 96 and 384 wells | RAININ | ||
| Mutil-channel pipette | RAININ | E4XLS | |
| Amicon concentrator | Merck | UFC803096 |
Access restricted. Please log in or start a trial to view this content.